On January 7, 2023, Mirum Pharmaceuticals, Inc. and Ian Clements, Ph.D. entered into a Transition, Separation and Consulting Agreement, dated January 7, 2023 (the Agreement), pursuant to which Dr. Clements will resign as Chief Financial Officer of the Company. Pursuant to the Agreement, Dr. Clements will continue his employment with the Company in the role of Chief Financial Officer from the effective date of the Agreement through May 15, 2023 unless such date is extended by mutual agreement or Dr. Clements' employment is terminated earlier in accordance with the terms of the Agreement (the Transition Period). Following the end of the Transition Period and subject to the terms and conditions of the Agreement, Dr. Clements will serve as a consultant to the Company for a period of 12 months unless such consulting arrangement is terminated earlier in accordance with the Agreement (the Consulting Period).
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
24.44 USD | -1.23% | -1.25% | -17.17% |
May. 10 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
May. 08 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.17% | 1.17B | |
+33.95% | 50.85B | |
+0.74% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+10.95% | 26.11B | |
-21.61% | 19.13B | |
+9.27% | 13.05B | |
+27.66% | 12.16B | |
+23.99% | 12.08B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Mirum Pharmaceuticals, Inc. Announces Resignation of Ian Clements as Chief Financial Officer